[go: up one dir, main page]

BR9710629A - Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto - Google Patents

Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto

Info

Publication number
BR9710629A
BR9710629A BR9710629A BR9710629A BR9710629A BR 9710629 A BR9710629 A BR 9710629A BR 9710629 A BR9710629 A BR 9710629A BR 9710629 A BR9710629 A BR 9710629A BR 9710629 A BR9710629 A BR 9710629A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
therapeutic agent
composition process
preparation
Prior art date
Application number
BR9710629A
Other languages
English (en)
Inventor
Henri Vial
Marie-Laure Ancelin
Michele Calas
Louis Giral
Original Assignee
Virbac Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virbac Sa filed Critical Virbac Sa
Publication of BR9710629A publication Critical patent/BR9710629A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/90—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR9710629A 1996-07-31 1997-07-17 Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto BR9710629A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609678A FR2751967B1 (fr) 1996-07-31 1996-07-31 Agents antipaludeens et antibabesioses et compositions pharmaceutiques les contenant
PCT/FR1997/001336 WO1998004252A1 (fr) 1996-07-31 1997-07-17 Agents antipaludeens et antibabesioses et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
BR9710629A true BR9710629A (pt) 1999-08-17

Family

ID=9494699

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710629A BR9710629A (pt) 1996-07-31 1997-07-17 Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto

Country Status (11)

Country Link
EP (1) EP0917465B1 (pt)
JP (1) JP2000515877A (pt)
KR (1) KR20000029690A (pt)
CN (1) CN100338046C (pt)
AT (1) ATE227984T1 (pt)
BR (1) BR9710629A (pt)
CA (1) CA2261851A1 (pt)
DE (1) DE69717279T2 (pt)
ES (1) ES2186909T3 (pt)
FR (1) FR2751967B1 (pt)
WO (1) WO1998004252A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796642B1 (fr) * 1999-07-21 2001-10-19 Centre Nat Rech Scient Precurseurs de sels de bis-ammonium quaternaire et leurs applications comme prodrogues ayant une activite anti-parasitaire
JP2007510672A (ja) * 2003-11-13 2007-04-26 ザ・ユニバーシティ・オブ・シドニー ビス−陽イオン化合物およびそれらの使用
AU2004289375B2 (en) * 2003-11-13 2010-12-23 The University Of Sydney Bis-cationic compounds and use thereof
CN101711527B (zh) * 2009-12-31 2013-02-20 蚌埠丰原医药科技发展有限公司 一种杀菌组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725718B1 (fr) * 1994-10-14 1997-01-24 Virbac Lab Bis-2-aminopyridines, leur procede de preparation et leurs applications

Also Published As

Publication number Publication date
KR20000029690A (ko) 2000-05-25
ES2186909T3 (es) 2003-05-16
FR2751967B1 (fr) 1998-10-09
EP0917465A1 (fr) 1999-05-26
EP0917465B1 (fr) 2002-11-20
CA2261851A1 (fr) 1998-02-05
CN1232388A (zh) 1999-10-20
DE69717279T2 (de) 2003-08-28
JP2000515877A (ja) 2000-11-28
FR2751967A1 (fr) 1998-02-06
ATE227984T1 (de) 2002-12-15
CN100338046C (zh) 2007-09-19
DE69717279D1 (de) 2003-01-02
WO1998004252A1 (fr) 1998-02-05

Similar Documents

Publication Publication Date Title
FR2694290B1 (fr) Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
PT91246A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao endovenosa, contendo ciclosporina como ingrediente activo
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
ATE292453T1 (de) Antivirale arznei
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
BR0012610A (pt) Novo derivado de difenilpiperidina
FR2715402B1 (fr) Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
PT1140031E (pt) Preparacao farmaceutica de libertacao controlada com mesilato de tilidina como substancia activa
EE03663B1 (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas
BR9404225A (pt) Formulação de substância ativa, aplicação, composições, medicamentos e processo para a preparação das formulações
BR9800718B1 (pt) composto esteróide tendo atividade contraceptiva, anti-osteoporose e para prevenir e tratar queixas da menopausa, composição farmacêutica, uso de um composto esteróide, e, processo para a preparação de um esteróide 16, 17 anelado.
FI853228A7 (fi) Uudet -butyrolaktaamit, niiden farmaseuttisesti aktiiviset koostumukset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkeaineina.
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DE ACORDO COM ART. 8O DA LPI.